SNY vs VRTX
Sanofi vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
SNY
Sanofi
62
Insufficient Data
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | SNY | VRTX |
|---|
| AI Score |
62
|
66
|
| Price |
$43.56
|
$529.70
|
| P/E Ratio |
23.06×
|
30.58×
|
| ROE |
10.9%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
86.0%
|
| Debt / Equity |
0.34×
|
0.00×
|
| Dividend Yield |
5.5%
|
0.0%
|
| RSI (14) |
53.1
|
80.4
|
| Beta |
0.278
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for SNY versus VRTX.
VRTX leads by 4 points.
VRTX scores 66/100 (Buy) versus SNY at 62/100 (Insufficient Data).
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical